CY2039B1 - 5-HT 1-like receptor agonist for rectal administration - Google Patents

5-HT 1-like receptor agonist for rectal administration

Info

Publication number
CY2039B1
CY2039B1 CY9802039A CY9802039A CY2039B1 CY 2039 B1 CY2039 B1 CY 2039B1 CY 9802039 A CY9802039 A CY 9802039A CY 9802039 A CY9802039 A CY 9802039A CY 2039 B1 CY2039 B1 CY 2039B1
Authority
CY
Cyprus
Prior art keywords
pct
receptor agonist
rectal administration
sec
date
Prior art date
Application number
CY9802039A
Other languages
English (en)
Original Assignee
Glaxo Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Sa filed Critical Glaxo Lab Sa
Publication of CY2039B1 publication Critical patent/CY2039B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CY9802039A 1992-05-07 1998-04-30 5-HT 1-like receptor agonist for rectal administration CY2039B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209882A GB9209882D0 (en) 1992-05-07 1992-05-07 Compositions

Publications (1)

Publication Number Publication Date
CY2039B1 true CY2039B1 (en) 1998-04-30

Family

ID=10715158

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9802039A CY2039B1 (en) 1992-05-07 1998-04-30 5-HT 1-like receptor agonist for rectal administration

Country Status (33)

Country Link
US (1) US5705506A (OSRAM)
EP (1) EP0639072B1 (OSRAM)
JP (1) JPH07506570A (OSRAM)
KR (1) KR100253111B1 (OSRAM)
AT (1) ATE163850T1 (OSRAM)
AU (1) AU670083B2 (OSRAM)
BE (1) BE1007024A5 (OSRAM)
BG (1) BG62120B1 (OSRAM)
BR (1) BR1100108A (OSRAM)
CA (1) CA2135179C (OSRAM)
CH (1) CH685920A5 (OSRAM)
CY (1) CY2039B1 (OSRAM)
CZ (1) CZ283512B6 (OSRAM)
DE (1) DE69317418T2 (OSRAM)
ES (1) ES2113533T3 (OSRAM)
FR (1) FR2690847B1 (OSRAM)
GB (2) GB9209882D0 (OSRAM)
GR (1) GR3026584T3 (OSRAM)
HK (1) HK95697A (OSRAM)
HU (2) HU227338B1 (OSRAM)
IE (1) IE75203B1 (OSRAM)
IL (1) IL105468A (OSRAM)
IT (1) IT1261471B (OSRAM)
NO (1) NO306700B1 (OSRAM)
NZ (1) NZ252132A (OSRAM)
OA (1) OA10109A (OSRAM)
RO (1) RO112993B1 (OSRAM)
RU (1) RU2118527C1 (OSRAM)
SG (1) SG46649A1 (OSRAM)
TW (1) TW231970B (OSRAM)
UA (1) UA37206C2 (OSRAM)
WO (1) WO1993021916A1 (OSRAM)
ZA (1) ZA933178B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2434297A (en) * 1996-05-23 1997-12-09 Alcon Laboratories, Inc. The use of 5-ht1b/1d agonists to treat ocular pain
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
PT2198858E (pt) * 1998-03-26 2011-09-01 Astellas Pharma Inc Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
WO2000051624A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
AR056690A1 (es) * 2005-10-14 2007-10-17 Athersys Inc Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
CA2749273C (en) 2008-01-09 2018-09-04 Charleston Laboratories, Inc. Pharmaceutical oral dosage form comprising a triptan and an antiemetic
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
CN103402514B (zh) 2010-10-15 2016-01-13 康特拉医药公司 用于治疗运动障碍的血清素受体激动剂组合物
HUE037732T2 (hu) 2012-04-18 2018-09-28 Contera Pharma Aps A mozgászavarok fejlett kezelésére alkalmas, szájon át szedhetõ gyógyszerészeti készítmény
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
CA3030089C (en) 2016-07-11 2024-04-23 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU550010B2 (en) * 1980-08-12 1986-02-27 Glaxo Group Limited 5-tryptaminoacetamides, carbamates and ureas
GB2082175B (en) * 1980-08-12 1984-05-02 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
GR79215B (OSRAM) * 1982-06-07 1984-10-22 Glaxo Group Ltd
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
US4785016A (en) * 1984-12-04 1988-11-15 Glaxo Group Limited Indole derivatives
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
EP0225726B1 (en) * 1985-11-08 1991-04-17 Glaxo Group Limited Indole derivatives
FI92397C (fi) * 1987-08-13 1994-11-10 Glaxo Group Ltd Menetelmä valmistaa farmaseuttisesti käyttökelpoisia indolijohdoksia
MC2210A1 (fr) * 1990-06-07 1992-11-26 Wellcome Found Composes heterocycliques therapeutiques,leur utilisation et procede pour les preparer

Also Published As

Publication number Publication date
GB9209882D0 (en) 1992-06-24
ITRM930286A0 (it) 1993-05-06
DE69317418D1 (de) 1998-04-16
CH685920A5 (fr) 1995-11-15
CA2135179A1 (en) 1993-11-11
AU4064093A (en) 1993-11-29
CZ283512B6 (cs) 1998-04-15
DE69317418T2 (de) 1998-07-30
HUT71418A (en) 1995-11-28
KR100253111B1 (en) 2000-07-01
AU670083B2 (en) 1996-07-04
HU211638A9 (en) 1995-12-28
GR3026584T3 (en) 1998-07-31
US5705506A (en) 1998-01-06
FR2690847B1 (fr) 1995-06-09
CZ272394A3 (en) 1995-10-18
NO306700B1 (no) 1999-12-13
NO944214L (no) 1994-11-07
ATE163850T1 (de) 1998-03-15
EP0639072A1 (en) 1995-02-22
BG99167A (bg) 1995-06-30
SG46649A1 (en) 1998-02-20
NZ252132A (en) 1996-09-25
ITRM930286A1 (it) 1994-11-06
GB2266665B (en) 1996-05-22
UA37206C2 (uk) 2001-05-15
GB9309209D0 (en) 1993-06-16
BG62120B1 (bg) 1999-03-31
IE930339A1 (en) 1993-11-17
IE75203B1 (en) 1997-08-27
IL105468A0 (en) 1993-08-18
RO112993B1 (ro) 1998-03-30
RU2118527C1 (ru) 1998-09-10
EP0639072B1 (en) 1998-03-11
GB2266665A (en) 1993-11-10
TW231970B (OSRAM) 1994-10-11
BE1007024A5 (fr) 1995-02-21
ZA933178B (en) 1994-01-10
FR2690847A1 (fr) 1993-11-12
HU227338B1 (en) 2011-04-28
CA2135179C (en) 2000-12-05
BR1100108A (pt) 1999-12-07
NO944214D0 (no) 1994-11-04
IL105468A (en) 1998-09-24
JPH07506570A (ja) 1995-07-20
OA10109A (en) 1996-12-18
WO1993021916A1 (en) 1993-11-11
ES2113533T3 (es) 1998-05-01
HK95697A (en) 1997-08-08
IT1261471B (it) 1996-05-23

Similar Documents

Publication Publication Date Title
MX9702865A (es) Agentes estrogenicos.
EP0903349A3 (en) CCR-3 receptor antagonists
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
ZA971279B (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors
EA200000299A1 (ru) Лекарства
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
AU5879299A (en) Adenine derivatives
CY2039B1 (en) 5-HT 1-like receptor agonist for rectal administration
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
NZ333385A (en) Solid oral dosage forms containing 35% of valsartan
UA66861C2 (uk) 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
MX9505064A (es) Composicion farmaceutica, aplicable oralmente.
GR3030919T3 (en) Selective system scan for multizone radiotelephone subscriber units.
GR3022615T3 (en) Pharmaceutical compositions based on ebastime or analogues thereof.
WO2000000198A8 (en) Piperidine derivatives having effects on serotonin related systems
NZ331683A (en) New indole and indazole compounds, a process for their preparation and pharmaceutical compositions containing them
GR3036195T3 (en) Novel compounds
BG102229A (en) Endothelium receptor antagonists
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
ATE162946T1 (de) Pharmazeutische zusammensetzungen enthaltend contignasterol-verbindungen
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих
ES2141671A1 (es) Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.